Hammwöhner M - Search Results

1

G-CSF-induced mobilization of CD34(+) progenitor cells and proarrhythmic effects in patients with severe coronary artery disease.

Wolfram O, Jentsch-Ullrich K, Wagner A, Hammwöhner M, Steinke R, Franke A, Zupan I, Klein HU, Goette A. Wolfram O, et al. Among authors: hammwohner m. Pacing Clin Electrophysiol. 2007 Jan;30 Suppl 1:S166-9. doi: 10.1111/j.1540-8159.2007.00630.x. Pacing Clin Electrophysiol. 2007. PMID: 17302697 Clinical Trial.

2

Cardiac uptake of progenitor cells in patients with moderate-to-severe left ventricular failure scheduled for cardiac resynchronization therapy.

Goette A, Jentsch-Ullrich K, Hammwöhner M, Trautmann S, Franke A, Klein HU, Auricchio A. Goette A, et al. Among authors: hammwohner m. Europace. 2006 Mar;8(3):157-60. doi: 10.1093/europace/euj042. Epub 2006 Feb 14. Europace. 2006. PMID: 16627431

3

New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation.

Hammwöhner M, D'Alessandro A, Wolfram O, Goette A. Hammwöhner M, et al. Curr Vasc Pharmacol. 2007 Jul;5(3):211-9. doi: 10.2174/157016107781024118. Curr Vasc Pharmacol. 2007. PMID: 17627564 Review.

4

New drugs for atrial fibrillation.

Hammwöhner M, Smid J, Lendeckel U, Goette A. Hammwöhner M, et al. J Interv Card Electrophysiol. 2008 Oct;23(1):15-21. doi: 10.1007/s10840-008-9278-2. Epub 2008 Jun 6. J Interv Card Electrophysiol. 2008. PMID: 18535890 Review.

5

Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.

Hammwöhner M, Goette A. Hammwöhner M, et al. J Cardiovasc Pharmacol. 2008 Jul;52(1):18-27. doi: 10.1097/FJC.0b013e318177e1f2. J Cardiovasc Pharmacol. 2008. PMID: 18594479 Review.

6

Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction.

Lehmann HI, Goette A, Martens-Lobenhoffer J, Hammwöhner M, Röhl FW, Bukowska A, Ghanem A, Klein HU, Bode-Böger SM. Lehmann HI, et al. Among authors: hammwohner m. Europace. 2011 Oct;13(10):1428-35. doi: 10.1093/europace/eur171. Epub 2011 Jul 13. Europace. 2011. PMID: 21752828

7

The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?

Hammwöhner M, Goette A. Hammwöhner M, et al. J Cardiovasc Pharmacol. 2015 Dec;66(6):530-9. doi: 10.1097/FJC.0000000000000297. J Cardiovasc Pharmacol. 2015. PMID: 26222990 Review.

8

Kidney diseases and NOAC therapy: Is there a light at the end of the tunnel?

Hammwöhner M, Goette A. Hammwöhner M, et al. Int J Cardiol. 2017 Jun 1;236:162-163. doi: 10.1016/j.ijcard.2017.01.066. Epub 2017 Jan 10. Int J Cardiol. 2017. PMID: 28096038 No abstract available.

9

The safety of edoxaban for treating atrial fibrillation.

Hammwöhner M, Goette A. Hammwöhner M, et al. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Expert Opin Drug Saf. 2017. PMID: 28862063 Review.

10

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?

Hammwöhner M, Goette A. Hammwöhner M, et al. Eur Heart J Suppl. 2020 Dec 22;22(Suppl O):O28-O41. doi: 10.1093/eurheartj/suaa177. eCollection 2020 Dec. Eur Heart J Suppl. 2020. PMID: 33380942 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters